

Balaxi Pharmaceuticals Limited

May 29, 2023

To,
Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

NSE Symbol: BALAXI

Dear Sir/Madam,

Subject: Disclosure of related party transactions for the half year ended March 31, 2023

Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the disclosure of related party transactions for the half year ended March 31, 2023.

The aforesaid information is also being hosted on the Company's website at www.balaxipharma.in.

This is for your information and records.

Yours Faithfully,

For **Balaxi Pharmaceuticals Limited**

Udayan Shukla
(Company Secretary and Compliance Officer)
Membership No.: F11744

Encl: A/a

Registered Office:

Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase III, Road No. 81, Jubilee Hills, Hyderabad (T.G.) - 500 096

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in

32	BALAXI GLOBAL DMCC	BALAXI HEALTHCARE GUATEMALA, SOCIEDAD ANONIMA	wholly owned subsidiary	investment		-	390.89	390.89											
33	BALAXI GLOBAL DMCC	BALAXI HEALTHCARE HONDURAS S. DE R.L	wholly owned subsidiary	investment		-	7.59	7.59											
34	BALAXI GLOBAL DMCC	BALAXI HEALTHCARE EL SALVADOR SA DE	wholly owned subsidiary	investment		-	1.52	1.52											
35	BALAXI GLOBAL DMCC	BALAXI HEALTHCARE CENTRAFRIQUE SARL	wholly owned subsidiary	investment		-	2.76	2.76											
36	BALAXI GLOBAL DMCC	BALAXI HEALTHCARE ANGOLA LDA	wholly owned subsidiary	investment		-	848.26	848.26											
37	BALAXI PHARMACEUTICALS LIMITED	Ashish Maheshwari	Managing Director	Remuneration to Director	40.00	40.00	-	-											
38	BALAXI PHARMACEUTICALS LIMITED	Pranav Maheshwari	Senior Vice President - Business Development	Remuneration to Relative of Director	20.00	20.00	-	-											
39	BALAXI GLOBAL DMCC	Paridhi Maheshwari	Head - Alternate Channels	Remuneration to Relative of Director	30.00	29.00	-	-											
40	BALAXI GLOBAL DMCC	Amol Anand Mantri	Chief Financial Officer	Remuneration to CFO	Not Applicable	96.24	-	-											
41	BALAXI PHARMACEUTICALS LIMITED	Udayan Shukla	Company Secretary	Remuneration to Company Secretary	10.98	10.25	-	-											
42	BALAXI PHARMACEUTICALS LIMITED	Ashish Maheshwari	Managing Director	Reimbursement of Expenses	2.82	2.82	-	-											
43	BALAXI PHARMACEUTICALS LIMITED	Minoshi Maheshwari	Director	Reimbursement of Expenses	13.77	13.77	-	-											
44	BALAXI PHARMACEUTICALS LIMITED	Ashish Maheshwari	Managing Director	Sitting Fee	1.00	1.00	-	-											
45	BALAXI PHARMACEUTICALS LIMITED	Minoshi Maheshwari	Director	Sitting Fee	0.50	0.50	-	-											
46	BALAXI PHARMACEUTICALS LIMITED	Gandhi Gamji	Director	Sitting Fee	0.50	0.50	-	-											
47	BALAXI PHARMACEUTICALS LIMITED	Kunal Mahendra Bhakta	Director	Sitting Fee	1.00	1.00	-	-											
48	BALAXI PHARMACEUTICALS LIMITED	M Srinivas Rao	Director	Sitting Fee	1.00	1.00	-	-											
49	BALAXI PHARMACEUTICALS LIMITED	Purnima Kamble	Director	Sitting Fee	1.00	1.00	-	-											
50	BALAXI PHARMACEUTICALS LIMITED	BALAXI FOUNDATION	Society Formed by the Company	CSR Expenses	15.00	13.98	-	-											
	Total					15,338.86													

Notes:

- The details in this format are required to be provided for all transactions undertaken during the reporting period. However, opening and closing balances, including commitments, to be disclosed for existing related party transactions even if there is no new related party transaction during the reporting period.
- Where a transaction is undertaken between members of the consolidated entity (between the listed entity and its subsidiary or between subsidiaries), it may be reported once.
- Listed banks shall not be required to provide the disclosures with respect to related party transactions involving loans, inter-corporate deposits, advances or investments made or given by the listed banks.
- For companies with financial year ending March 31, this information has to be provided for six months ended September 30 and six months ended March 31. Companies with financial years ending in other months, the six months period shall apply accordingly
Each type of related party transaction (for e.g. sale of goods/services, purchase of goods/services or whether it involves a loan, inter-corporate deposit, advance or investment) with a single party shall be disclosed separately and there should be no clubbing or netting of transactions of same type. However, transactions with the same counterparty of the same type may be aggregated for the reporting period. For instance, sale transactions with the same party may be aggregated for the reporting period and purchase transactions may also be disclosed in a similar manner. There should be no netting off for sale and purchase transactions. Similarly, loans advanced to and received from the same counterparty should be disclosed separately, without any netting off.
- In case of a multi-year related party transaction:
 - The aggregate value of such related party transaction as approved by the audit committee shall be disclosed in the column "Value of the related party transaction as approved by the audit committee".
 - The value of the related party transaction undertaken in the reporting period shall be reported in the column "Value of related party transaction during the reporting period".
- "Cost" refers to the cost of borrowed funds for the listed entity.
- PAN will not be displayed on the website of the Stock Exchange(s).
- Transactions such as acceptance of fixed deposits by banks/NBFCs, undertaken with related parties, at the terms uniformly applicable /offered to all shareholders/ public shall also be reported.